Clinical Trial Update: Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety and efficacy of Sup19 CAR-T cells in patients with previously treated or CD19-weakly expressed hematologic tumors; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia Lymphoma

Drugs mentioned

• Sup19 CAR-T cells

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: B-Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING